Rollover Study Of Lapatinib In Cancer Patients
An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- GSK Investigational Site
-
-
-
-
-
Tel Aviv, Israel, 64239
- GSK Investigational Site
-
-
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- GSK Investigational Site
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- GSK Investigational Site
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- GSK Investigational Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- GSK Investigational Site
-
Durham, North Carolina, United States, 27705
- GSK Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- GSK Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- GSK Investigational Site
-
-
Texas
-
San Antonio, Texas, United States, 78229
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Currently receiving clinical benefit as defined by CR, PR or SD from treatment with lapatinib through participation in a Phase I study of lapatinib either as monotherapy or as part of a combination regimen.
- Ability to understand and provide written informed consent to participate in this trial.
- Is male or female.
- Female and male subjects agree to the protocol specific birth control measures
Exclusion Criteria:
- Permanent discontinuation of lapatinib in the previous study due to intolerance or treatment failure.
- Is a pregnant or lactating female.
- Is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or screening investigations.
- Currently receiving treatment with any medications listed on the prohibited medication list (see Section 7.2).
- Has Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.
- Has a left ventricular ejection fraction (LVEF) < 40% based on MUGA or ECHO.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1
Lapatinib either 750, 1000, 1250 or 1500 mgs
|
Lapatinib either at 750, 1000, 1250 or 1500 mgs
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To determine the long-term safety and tolerability of lapatinib as monotherapy or in combination regimen
Time Frame: Ongoing study until the new lapatinib rollover study, EGF111767, is approved at the current sites.
|
Ongoing study until the new lapatinib rollover study, EGF111767, is approved at the current sites.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients, Overall survival
Time Frame: Ongoing study until the new lapatinib rollover study, EGF111767, is approved at the current sites.
|
Ongoing study until the new lapatinib rollover study, EGF111767, is approved at the current sites.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EGF19060
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.